Emerging Trends and Global Future Forecast of Ventilators Market

Rising prevalence of respiratory diseases, increasing incidence of preterm births, urbanization and growing pollution levels, high prevalence of tobacco smoking, rapid growth in the geriatric population, and rising number of ICU beds are the major factors driving the growth of the ventilators market.

The global Ventilator Market is projected to reach USD 1,261.9 Million by 2023 from USD 859.9 Million in 2018, at a CAGR of 8.0%.

On the basis of mobility, the intensive case ventilators segment accounted for the largest share of the global ventilators market. The large share of this segment is attributed to the rising number of ICU beds and rising adoption of equipping the ICU beds with ventilators.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11018337

On the basis of interface, the invasive ventilation segment accounted for the largest share of the ventilators market. The large share of this segment is due to the high prevalence of tobacco smoking, increasing prevalence of chronic diseases such as COPD & asthma, rapid growth in the geriatric population, and improving healthcare affordability in developed countries.
Based on end user, the hospitals & clinics segment accounted for the largest share of the ventilators market. The large share of this segment can be attributed to the increasing number of private and public hospitals, economic expansion and focus of government on broader healthcare policies, and increasing per capita income.

Based on type, the adult/pediatric ventilators segment held the largest market share of ventilators market. The large share of this segment can be attributed to the large patient population with severe COPD, asthma, and other chronic respiratory diseases; rising number of smokers; and rapid growth in the geriatric population.

Regional Analysis:-
North America accounted for the largest share of the ventilators market in 2017, followed by Europe and Asia Pacific. The presence of major market players, the rising geriatric population, high prevalence of smoking, high prevalence of respiratory diseases, highly developed healthcare system, and high healthcare expenditure are the other factors responsible for the large share of North America in the ventilators market.

Read more - https://www.marketsandmarkets.com/PressReleases/ventilators.asp

Top Key Players:-
The prominent players in the global ventilators market are Philips Healthcare (Netherlands), ResMed (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Getinge (Sweden), Dräger (Germany), Smiths Group (UK), Hamilton Medical (Switzerland), GE Healthcare (US), Fisher & Paykel (New Zealand), Air Liquide (France), Zoll Medical (US), Allied Healthcare Products (US), Airon (US), Mindray (China), and Schiller (Switzerland).

Technological Innovation in ECG Cable and ECG Lead wires Market

Growth in this market can primarily be attributed to factors such as the rapidly increasing aging population, technological advancement, favoring government regulations towards monitoring devices and increasing incidences of cardiovascular diseases.

The ECG Cable and ECG Lead wires Market witnessed considerable growth during the last decade and is expected to grow at a CAGR of 5.7% between 2016 and 2021 to reach USD 1.75 Billion by 2021.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=34598493

The ECG cables and ECG leadwires market is segmented based on material, usability, leadwires by machine type, patient care setting and regions.

Based on ECG cables and ECG leadwires by materials, the market is split into three, namely, TPU (Thermoplastic polyurethane), TPE (Thermoplastic elastomer) and others (Silicone, PVC). Based on usability, the ECG cables and ECG leadwires market is divided into reusable and disposable.
Based on leadwires by type, the ECG leadwires market is segmented into single-lead ECG leadwire, 3-lead ECG leadwire, 5- lead ECG leadwire, 6- lead ECG leadwire, 12- lead ECG leadwire and other leadwires (15- and 18- lead ECG leadwires).

In 2015, the reusable segment accounted for the largest share in the global ECG cables and ECG leadwires market. And based on materials, the TPE (Thermoplastic elastomer) segment accounted for the largest share in the global ECG cables and ECG leadwires market.

Similarly, based on patient care setting, the ECG cables and ECG leadwires market is subsegmented into hospitals, clinics, long term care facilities and ambulatory and homecare. On the basis of geography, the ECG cables and ECG leadwires market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).

North America held the largest share in the ECG cables and ECG leadwires market owing to the growing aged population and demand for remote monitoring ECG devices. On the other hand, the Asia-Pacific (APAC) region is expected to witness the highest growth rate during the forecast period.

Read more: - https://www.marketsandmarkets.com/PressReleases/ecg-cable-and-lead-wire.asp

The market players namely, 3M Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc (Ireland), Koninklijke Philips N.V. (The Netherlands) and Mindray Medical International Limited (China), held major share of the ECG cables and ECG leadwires market. The companies majorly focused on strategies such as Agreements, partnerships, mergers, acquisitions and expansions to sustain their positions in the market.

Latest Technologies Transforming the Industrial Business US Outpatient Surgical Procedures Market

The growing number of outpatient surgeries is expected to increase the adoption of capnography monitoring devices in outpatient surgical departments in the US. The demand for capnography monitoring devices in outpatient surgical procedures is further supported by the increasing prevalence of target diseases (diabetes, CVDs, respiratory diseases, and sleep apnea) and the growing number of outpatient surgical procedures requiring general anesthesia and medium & high sedation.

The number of US Outpatient Surgical Procedures Market is expected to grow from ~129 million procedures in 2018 to ~144 million procedures by 2023, at a CAGR of 2.1% during the forecast period.

Download PDF Brochure: - 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94756744 

The major types of outpatient surgical procedures in the US include dental surgeries, gastrointestinal surgeries, orthopedic surgeries, ophthalmic surgeries, ENT surgeries, obstetric/gynecological surgeries, cosmetic surgeries, cardiovascular surgeries, urologic surgeries, and other surgeries.

By type, the dental surgeries segment accounted for the largest share of the market during the forecast period. However, the other surgeries segment is expected to grow at the highest CAGR during the forecast period.

Other surgeries performed in outpatient departments include surgeries of the nervous system (laminectomy and excision of the intervertebral disc and decompression of the peripheral nerve), endocrine system (partial or complete thyroidectomy), and integumentary system (mastectomy and lumpectomy).

Read More:-  

https://www.marketsandmarkets.com/PressReleases/us-outpatient-surgical-procedures.asp

Currently, outpatient surgeries are performed in hospital outpatient departments (HOPDs), ambulatory surgical centers (ASCs), and physicians’ offices in the US. Certain recommendations have been approved in the US for conducting surgeries in outpatient departments.

Urology Devices Market Growth, Trends, Revenue, Share - 2022

The global urology devices market is segmented by product, disease, end user, and regions. By product, the market is segmented into instruments and consumables & accessories. The instruments segment is estimated to account for the largest market share of the global market in 2017. Factors driving the growth of this segment include the increasing adoption of minimally invasive techniques in urology treatment and advances in technology to develop novel instruments.

The Urology Devices Market is expected to reach USD 44.37 Billion by 2022 from USD 31.44 Billion in 2017, at a CAGR of 7.1%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212

By product, the urology devices market is classified into instruments and consumables & accessories. The instruments segment is expected to lead the global urology devices market in 2017. Factors driving the growth of this segment include increasing adoption of urology devices in hospitals and clinics, rising incidence of chronic disorders, and increasing demand for minimally invasive surgeries in urology.

By disease, the market is segmented into kidney disease, urological cancer and BPH, pelvic organ prolapse. The kidney diseases segment is expected to account for the largest share of the global urology devices in 2017. A large number of products are used in the diagnosis and treatment of this segment which is a major factor responsible for the dominant share of this segment.
On the basis of end user, the urology devices market is categorized into hospitals and clinics, dialysis centers, and other end users. The hospitals and clinics segment is estimated to account for the largest share of the global urology devices market during the forecast period.

Regional Analysis:
Based on region, the urology devices market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the urology devices market in 2017. This is attributed to factors such as accessibility to advanced technologies and opportunities for advanced cancer diagnostic testing and screening, growing incidence of cancer, and technological advancements of urology devices in the region as compared to other regions.

Read more:- https://www.marketsandmarkets.com/PressReleases/urology-devices.asp

Top Key Players:
Key players in the urology devices market include Fresenius Medical Care (Germany), Baxter (US), Boston Scientific (US), Olympus (Japan), Richard Wolf (US), KARL STORZ (Germany), Cook Medical (US), Medtronic (US), C. R. Bard (US), Dornier MedTech (Germany), Prometheus Group (US), Medi-Globe (US), Intuitive Surgical (US), Merit Medical Systems (US), Siemens Healthcare (Germany), Stryker (US), ROCAMED (France), Medica (Italy), NOVAmedtek (Turkey), SRS Medical Systems (US), ProSurg (US), Albyn Medical (UK), EMD Medical Technologies (Canada), and Biolitec (Germany).

Increasing Government Investments to Develop Novel Cardiac Marker Testing

A number of factors such as growing incidences of cardiovascular diseases, the rapidly increasing geriatric population, growing funding from public–private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are fueling the growth of the cardiac marker testing market. On the other hand, technical problems related to sample collection and storage and issues related to regulatory and reimburse systems are some of the key factors limiting the growth of the global cardiac marker testing market.

This report studies the global Cardiac Marker Testing Market over the forecast period of 2016 to 2021. The market is expected to reach ~USD 3.50 Billion by 2021, at a CAGR of 8.8% from 2016 to 2021.

Download Free PDF Brochure: - http://www.marketsandmarkets.com/pdfdownload.asp?id=64885447

Based on type, the global cardiac marker testing market is divided into six segments, namely, troponin I and T, CK-MB, BNP or NT-proBNP, Myoglobin, hsCRP, and other biomarkers. The other biomarkers segment includes galectin-3, H-FABP, myeloperoxidase, ischemia-modified albumin, and homocysteine.

On the basis of product, the global cardiac marker testing market is segmented into reagents and kits and instruments. The instruments section is further segmented on the basis of method, namely, chemiluminescence, immunofluorescence, ELISA, and immunochromatography. On the basis of disease, the cardiac marker testing market is segmented into myocardial infarction and congestive heart failure.

On the basis of type of testing, the cardiac marker testing market is segmented into laboratory testing and point-of-care testing.

As of 2016, North America held the largest share of the global cardiac marker testing market, followed by Europe. However, the Asia-Pacific market is expected to register the highest CAGR of 11.7% from 2016 to 2021.

Factors such as rising prevalence and incidence of cardiovascular diseases and public-private initiatives to increase awareness about early cardiac disease diagnosis are stimulating the growth of the cardiac marker testing market in the Asia-Pacific region.

Read more: - https://www.marketsandmarkets.com/PressReleases/cardiac-marker-testing.asp

Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (U.S.), Siemens AG (Germany), Danaher Corporation (U.S.) Alere, Inc. (U.S.), bioMérieux SA (France), LSI Medience Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation, Japan), Ortho Clinical Diagnostics (a subsidiary of The Carlyle Group, U.S.), Randox laboratories Ltd (U.K.), and Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) (China) are some of the key players operating in the global cardiac marker testing market.

Emerging Trends and Global Future Forecast of Respiratory Diagnostics Market

Major factors driving the market growth are increasing prevalence of respiratory diseases, growing geriatric population, and technological advancements in respiratory diagnostic systems. On the other hand, rising healthcare costs and reimbursement concerns are the major factors restraining the growth of the respiratory diagnostics market. High potential emerging markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore offer significant growth opportunities for the key players in the respiratory diagnostics market.

The global Respiratory Diagnostics Market is projected to reach USD 7.45 Billion by 2021 from USD 5.24 Billion in 2016, at a CAGR of 7.3% from 2016 to 2021.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163390459

The global respiratory diagnostics market is segmented on the basis of product and service, test type, disease, end user, and region.

On the basis of product and service, the respiratory diagnostics market is segmented into instruments and devices, assays and reagents, and software and services. The instruments and devices segment is expected to account for the largest share of the respiratory diagnostics market in 2016. The continuous requirement of diagnostic instruments and devices in laboratories, point-of-care, and home care is a major factor driving the uptake of instruments and devices.

On the basis of test type, the respiratory diagnostics market is broadly classified into mechanical tests, imaging tests, traditional diagnostic tests, and molecular diagnostic tests. In 2016, the traditional diagnostic tests segment is expected to account for the largest share of the respiratory diagnostics market.

On the basis of disease, the respiratory diagnostics market is segmented into asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis, and other diseases. The tuberculosis segment is expected to account for the largest share of the respiratory diagnostics market in 2016.
On the basis of end user, the respiratory diagnostics market is categorized into hospital/clinical laboratories, reference laboratories, physician offices, and other end users (including blood banks, point-of-care testing, patient self-testing, home health agencies, nursing homes, and local public health laboratories).

Read more: - https://www.marketsandmarkets.com/PressReleases/respiratory-diagnostics.asp

Regional Analysis:-
North America is expected to account for the largest share of the global respiratory diagnostics market in 2016, followed by Europe. The growth of the respiratory diagnostics market in North America is majorly driven by the rising prevalence of respiratory diseases and growing geriatric population in the region. Other factors supporting the growth of this market include the presence of an advanced healthcare system and strong distribution channels for respiratory diagnostic products in North America.

Top Key Players:-
The respiratory diagnostics market is dominated by established players such as Philips Healthcare (Netherlands), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Alere, Inc. (U.S.).

New Approach towards Technological Advancements in Cholesterol Testing Services Market

Factors such as increasing incidence of cardiovascular diseases and obesity, physician preference of laboratory testing rather self-testing, growing awareness and adoption of preventive healthcare, government initiatives to improve the quality of testing, and rapid growth in the geriatric population are propelling the growth of this market. Moreover, emerging economies offer significant growth opportunities for players operating in the cholesterol testing services market. On the other hand, rapidly growing home/self-testing and emergence of noninvasive cholesterol testing methods are the major factors that may limit growth of the market to a certain extent.          

The global Cholesterol testing services Market is expected to reach USD 17.57 Billion by 2021 from an estimated value of USD 11.96 Billion in 2016, growing at a CAGR of 8% during the forecast period.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180941049

The cholesterol testing services market is segmented on the basis of type of customer and region. Based on type of customer, the market is segmented into physicians/providers and hospitals; employers, health plans, and Managed Care Organizations (MCOs); government agencies, Accountable Care Organizations (ACOs), and Integrated Delivery Networks (IDNs); and patients.
The patient-driven cholesterol testing segment is expected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness and adoption of preventive healthcare, availability of lab test services for patients without any physician intervention thus reducing the waiting time to get appointment from physicians, and online access to reports and readings through smartphones.

Based on region, the cholesterol testing services market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2016, North America is expected to dominate the market, followed by Europe. However, the cholesterol testing services market in the Asian region is expected to witness the highest CAGR during the forecast period mainly due to large population in the region, increased prevalence of cardiovascular diseases, increasing awareness in masses for preventive healthcare, and large number of testing facilities available in the Asian region.

Read More: - https://www.marketsandmarkets.com/PressReleases/cholesterol-testing-services.asp

Prominent players in the market include Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific (Luxembourg), Spectra Laboratories Inc. (U.S.), Unilabs (Switzerland), SYNLAB International GmbH (Germany), Bio-Reference Laboratories Inc. (U.S.), Clinical Reference Laboratory, Inc. (CRL) (U.S.), ACM Medical Laboratory (U.S.), and Adicon Clinical Laboratory (China).

Global Future forecast of Microtome Market

Microtome Market is experiencing significant growth due to the growing demand for increasing healthcare expenditure, digital pathology, and high prevalence of cancer. A lack of skilled professionals is likely to hamper the growth of the market.

The report Microtome Market  is expected to grow from USD 129 million in 2019 to reach USD 177 million by 2024, at a CAGR of 6.5%.

Microtomes operate on different technologies, including manual, semi-automated, and fully automated. Manual microtomes segment accounted for the largest market share in 2018. Manual microtomes are cost-effective and are easier to use as compared to automatic and semi-automatic modules. These factors are supporting their adoption in the market, and the trend is anticipated to continue over the forecast period.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=230495411

Clinical laboratories and hospital laboratories are the main end-users of microtomes, among others. In 2018, the hospital laboratories segment accounted for the largest market share and was expected to grow at the highest CAGR during the forecast period. The large share of the hospital laboratories segment is attributed to the increasing number of patient visits to hospitals, rising number of in-house clinical diagnostic procedures performed in hospitals, growing awareness regarding early diagnosis, and the availability of reimbursements in developed markets for clinical tests performed in hospitals.

Regional Analysis:-
By region, the microtomes market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe.

The easy accessibility to advanced technologies, growing opportunities for advanced cancer diagnostic testing and screening, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the microtomes market in North America.

Read More: - https://www.marketsandmarkets.com/PressReleases/microtomes.asp

Key Players:

The prominent players operating in the microtomes market include Thermo Fisher Scientific (US), Danaher Corporation (US), Sakura Finetek (Japan), SLEE Medical GmbH (Germany), MEDITE GmbH (Germany), Histo-Line Laboratories (Italy), Amos Scientific (Australia), RMC Boeckeler (US), Diapath S.p.A. (Italy), and Jinhua YIDI Medical Appliance (China).

Medical Image Analysis Software Market: An Outlook to the Future Global Opportunities

Market growth is driven by technological advancements in medical imaging systems and analysis software, growing public- and private-sector investments in the medical imaging market, increasing use of imaging equipment due to rising prevalence of chronic diseases, fusion of imaging technologies and growing applications of computer-aided diagnosis.

The report Medical Image Analysis Software Market is expected to reach USD 3.88 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 8.2% during the forecast period.

However, budgetary constraints are restraining the growth of this medical image analysis software market to a certain extent. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Major Market Developments

• In December 2016, Pickering Electronics Philips Healthcare (US) introduced Signed a 10-year partnership with Expert Group of Companies (Russia) to jointly improve the efficiency of the delivery of patient care in Russia. 
• In June 2015, Siemens Healthcare (Germany) signed a contract with William Osler Health System (Canada) to expand its presence in the Canadian market.
• In November 2015, Vital Images, Inc. (US) partnered with Heilind Electronics (US), a global distributor to expand the company’s sensor product line through Stratasys, Ltd. (US) to develop print-on-demand services using Vital’s industry-leading Vitrea advanced visualization software and Stratasys’ 3D printing services.

Market Drivers:-

• Technological advancements in medical imaging systems and analysis software
• Growing public- and private-sector investments in the medical imaging market
• Increasing use of imaging equipment due to rising prevalence of chronic diseases
• Fusion of imaging technologies
• Growing applications of computer-aided diagnosis

Regional Analysis:-
Of the various regions, North America is projected to account for the largest share of the global medical image analysis software market by 2022. A recently published report of the World Health Organization (WHO) stated that by 2020, chronic diseases would account for nearly 73% of all deaths and 60% of the global burden of disease. Moreover, the number of imaging centers is increasing in the region in tandem with the growing geriatric population and the increasing prevalence of various diseases.

Read more: - https://www.marketsandmarkets.com/PressReleases/medical-image-analysis.asp

Top Key Players:-
The increasing presence of new and established players in the medical image analysis software market is likely to intensify the competition. A few prominent market players operating in this market include AQUILAB (France), AGFA Healthcare (Belgium), Esaote S.p.A (Italy), Carestream Health, Inc. (US), and GE Healthcare (US).

Veterinary Imaging Market by Product, Animal, Therapeutic Area & End User- 2022

The growth of the market during the forecast period is mainly driven by the increase in animal healthcare spending, growing pet insurance purchase, the growing companion animals market, increase in the number of veterinary practitioners and their income levels in developed regions, and launch of portable battery charge imaging instruments. However, the high cost of veterinary imaging instruments and increasing pet care expenditure are expected to restrain the overall market growth, to a certain extent, during the forecast period.

The Veterinary Imaging Market is expected to reach USD 1.94 Billion by 2022 from an estimated USD 1.40 Billion in 2017, at a CAGR of 6.8%.

In this report, the global veterinary imaging market is segmented by product, therapeutic area, animal, end user, and region. On the basis of product, the global veterinary imaging market is segmented into instruments, reagents, and software. The veterinary imaging instruments segment includes radiography systems, ultrasound imaging systems, magnetic resonance imaging (MRI) systems, computed tomography (CT) imaging systems, video endoscopy imaging systems, and other imaging systems (including thermal imaging systems and optical coherent tomography).
The radiography systems segment accounted for the largest share of the global veterinary imaging instruments market in 2016.

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80889726   

On the basis of therapeutic area, the global veterinary imaging market is segmented into orthopedics & traumatology, oncology, cardiology, neurology, and other therapeutic areas. The orthopedics & traumatology segment accounted for the largest share of the global veterinary imaging market in 2016. The large share of this segment can be attributed to the increasing incidence of bone injuries and rising prevalence of arthritis and lameness disease in animals. Oncology application segment offers significant growth opportunities in the market.

Based on animal type, the global veterinary imaging market is segmented into small companion animals, large animals, and other animals. The small companion animals segment accounted for the largest share of the market in 2016. The large share and growth of this segment are attributed to the increasing adoption of companion animals, rising animal healthcare expenditure, growing demand for pet insurance in developed countries, and increasing incidence of disease outbreaks in companion animals.

The global veterinary imaging market, by end user, is segmented into clinics and hospitals & academic institutions. Clinics are the major end users in the veterinary imaging market and accounted for a share in 2016.

Regional Analysis:-
North America represented the largest veterinary imaging market in 2016, followed by Europe and Asia-Pacific. The Asia-Pacific market is expected to register the highest CAGR during the forecast period. Factors such as large increasing awareness about animal health in APAC countries, growth in pet adoption, and growing per capita animal health expenditure, especially in India and China, are contributing to the growth of the APAC veterinary imaging market.

Read more @ https://www.marketsandmarkets.com/PressReleases/veterinary-imaging.asp  

Key players:-
The major players in the global veterinary imaging market are GE Healthcare (U.S.), Agfa- Gevaert N.V. (Belgium), Excelsior Union Limited (Russia), Onex Corporation (Canada), Esaote S.p.A (Italy), Canon Inc. (Japan), IDEXX Laboratories, Inc. (U.S.), VCA Inc. (U.S.), Hitachi, Ltd (Japan), BCF Technology, Ltd. (U.K.), Siemens AG (Germany), Diagnostic Imaging Systems, Inc. (U.S.), Hallmarq Veterinary Imaging Ltd. (U.K.), MinXray, Inc. (U.S.), and Fujifilm Holdings Corporation (Japan).

Stem Cell Therapy Market | Emerging Countries Offer High-Growth Opportunities to Players in the Market

Stem cell therapy is a kind of procedure used for treating or preventing a disease from spreading further into the body. It is the fastest-growing as well as the largest segment under regenerative medicine. Stem cells have the capability to grow new cells, replicate themselves, or replace damaged cells in the body. Moreover, stem cell therapies are also used for treating various chronic diseases like cancer and other blood disorders, thereby boosting the growth of the market for stem cell therapy.

The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period.

Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.

Product Analysis

• Product Matrix which gives a detailed comparison of the product portfolios of the top five companies

Geographical Analysis

• Further breakdown of the North American stem cell therapy market into the US and Canada
• Further breakdown of the European stem cell therapy market into the UK, Germany, France, and Rest of Europe

Company Information

·         Detailed analysis and profiling of additional market players (Up to 5)

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

On the basis of therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. This large share can be attributed to the rising availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases, and growing patient preference for effective & early treatment strategies.

On the basis of cell source, the global stem cell therapy market is divided into adipose derived MSCs; bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Furthermore, the bone marrow derived MSCs segment is expected to grow at highest CAGR of 12.1% during the forecast period.

Read more (Stem Cell Therapy Market):-
https://www.marketsandmarkets.com/PressReleases/stem-cells-market.asp

The Major Players in this Market:

As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market.